GRI Bio implements 1-for-7 reverse stock split to regain Nasdaq compliance

GRI Bio, Inc.

Effective 4:01 p.m. ET Jan 29, 2024; post-split trading begins Jan 30 under symbol GRI.
Outstanding shares reduced from ~4,520,233 to ~645,736; authorized shares unchanged.
Proportional adjustments to per-share exercise price and shares issuable under outstanding options, warrants, and convertible securities.
No fractional shares issued; stockholders receive cash in lieu based on Jan 29 closing price.
Stockholder-approved at Jan 19 special meeting; intended to regain Nasdaq minimum bid price compliance.

item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

GRI Bio, Inc.: Amended certificate of incorporation to effect a 1-for-7 reverse stock split (effective 2024-01-29).

Change: charter amendment
Effective: 2024-01-29

Exact text from the filing

On January 29, 2024, GRI Bio, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation to effect a reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-7 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-24-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.